| 0 (0%) | 10-15 12:18 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 24.18 | 1-year : | 28.25 |
| Resists | First : | 20.7 | Second : | 24.18 |
| Pivot price | 19.76  |
|||
| Supports | First : | 19.16 | Second : | 18.2 |
| MAs | MA(5) : | 20.01 |
MA(20) : | 19.54 |
| MA(100) : | 17.75 |
MA(250) : | 17.55 |
|
| MACD | MACD : | 0.4 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 71.7 |
D(3) : | 72.7 |
| RSI | RSI(14): 57.2 |
|||
| 52-week | High : | 22.79 | Low : | 12.47 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ TEVA ] has closed below upper band by 45.2%. Bollinger Bands are 23.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 20.27 - 20.4 | 20.4 - 20.51 |
| Low: | 19.39 - 19.53 | 19.53 - 19.67 |
| Close: | 19.89 - 20.1 | 20.1 - 20.31 |
Wed, 15 Oct 2025
Value Drug sues Alkermes for allegedly delaying Vivitrol generic - Drug Store News
Wed, 15 Oct 2025
Cold Chain Technologies enables ocean freight breakthrough for Teva and Kuehne+Nagel - Container News
Wed, 15 Oct 2025
The Bull Case For Teva (TEVA) Could Change Following UZEDY's FDA Approval for Bipolar I Disorder Expansion - simplywall.st
Wed, 15 Oct 2025
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Tue, 14 Oct 2025
Cold Chain Technologies enables sea freight success for Teva and Kuehne+Nagel - American Journal of Transportation
Mon, 13 Oct 2025
SystImmune’s $250M milestone; Teva’s Uzedy approved to treat bipolar disorder - Endpoints News
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 1,150 (M) |
| Shares Float | 1,140 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 64.7 (%) |
| Shares Short | 49,880 (K) |
| Shares Short P.Month | 50,510 (K) |
| EPS | -0.16 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.94 |
| Profit Margin | -1 % |
| Operating Margin | 21.4 % |
| Return on Assets (ttm) | 5.3 % |
| Return on Equity (ttm) | -2.5 % |
| Qtrly Rev. Growth | 0.3 % |
| Gross Profit (p.s.) | 7.17 |
| Sales Per Share | 14.46 |
| EBITDA (p.s.) | 3.93 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 1,390 (M) |
| Levered Free Cash Flow | 1,600 (M) |
| PE Ratio | -132.57 |
| PEG Ratio | 0 |
| Price to Book value | 3.34 |
| Price to Sales | 1.37 |
| Price to Cash Flow | 16.45 |
| Dividend | 0.09 |
| Forward Dividend | 0 |
| Dividend Yield | 0.4% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|